Literature DB >> 17708162

Tissue and plasma concentrations of cephuroxime during cardiac surgery in cardiopulmonary bypass--a microdialysis study.

J Mand'ák1, M Pojar, J Maláková, V Lonsk, V Palicka, P Zivný.   

Abstract

AIM: Wound and mediastinal infections are still very serious complications of open-heart surgery, in spite of the use of prophylactic antibiotics. The use of cardiopulmonary bypass (CPB) is associated with profound physiological changes affecting the pharmacokinetic behaviour of antibiotics. The aim of this pilot study was to monitor the tissue concentrations of cephuroxime (prophylactic antibiotic) in skeletal muscle during cardiac surgery using CPB by interstitial microdialysis. These concentrations were compared with plasma concentrations of cephuroxime.
MATERIAL AND METHODS: Nine adult patients operated on using CPB were enrolled in this study. Cephuroxime was used as a prophylactic antibiotic (1st dose - 3 g of cefuroxime i.v. with anesthesia induction, 2nd dose - 1.5 g i.v. after CPB with protamine sulphate, 3rd dose - 1.5 g i.v. 8 hours after the surgery). Interstitial microdialysis was performed by probe CMA 60 (CMA Microdialysis AB, Sweden) inserted into the patient's deltoid muscle. Concentrations of cephuroxime in dialysates and in plasma were determined by the modified fluid chromatography method. The unbound cephuroxime fraction in plasma was obtained by using an ultrafiltration method. Samples of dialysates were collected at the following intervals: before CPB, each 30 minutes of CPB, at the end of CPB. Samples of blood were collected at these intervals: incision, start of CPB, each 30 minutes of CPB, at the end of CPB, at the end of surgery. Concentrations of cephuroxime in tissue were corrected by in vivo recoveries of the microdialysis probes.
RESULTS: Plasma concentrations of cephuroxime were 163.5 +/- 40.1, 79.3 +/- 17.4, 73.7 +/- 16.8, 66.1 +/- 18.3, 57.0 +/- 10.9, 120.7 +/- 29.9 (mg L(-1)) and concentrations of free plasma fraction of cephuroxime were 119.5 +/- 35.2, 67.8 +/- 15.5, 66.0 +/- 12.5, 54.8 +/- 12.2, 49.6 +/- 9.8, 102.6 +/-26.0 (mg L(-1)). The concentrations of cephuroxime in dialysates were 44.3 +/- 15.7, 36.1 +/- 11.6, 31.9 +/- 9.3, 34.6 +/- 12.3, 27.6 +/-12.9, 56.7 +/- 17.6 (mg L(-1)). The mean in vivo recovery of cephuroxime in this study was 30%. Corrected concentrations (calculated by in vivo recovery) of cephuroxime in skeletal muscle were 148, 120, 106, 115, 92, 189 (mg L(-l)).
CONCLUSION: Our preliminary results show that CPB can modify the time course of cephuroxime plasma and tissue concentrations. A decrease in plasma drug concentrations occurred at the start of CPB and lasted until CPB ended. An increase in plasma concentrations corresponds to the second drug dose after CPB. The concentrations of cephuroxime in skeletal muscle (corrected by recovery) during CPB are higher than plasma concentrations. It is influenced by important changes during CPB; closely associated with hemodilution, a shift of intravascular volume, solutes and albumin to the extravascular space and inconstant protein binding of cephuroxime during operation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17708162     DOI: 10.1177/0267659107080116

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  10 in total

Review 1.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 2.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Blood concentrations of cefuroxime in cardiopulmonary bypass surgery.

Authors:  Daphne Bertholee; Peter G J ter Horst; Michel L Hijmering; Alexander J Spanjersberg; Wobbe Hospes; Bob Wilffert
Journal:  Int J Clin Pharm       Date:  2013-06-21

4.  Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 6.  Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?

Authors:  Jennifer H Huang; Rachel Sunstrom; Myrna Y Munar; Ganesh Cherala; Arthur Legg; Ali J Olyeai; Stephen M Langley
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-15       Impact factor: 5.209

7.  Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery.

Authors:  Ralph Gertler; Michael Gruber; Gunther Wiesner; Stanislas Grassin-Delyle; Saïk Urien; Peter Tassani-Prell; Klaus Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-15       Impact factor: 4.335

8.  Pharmacokinetic Model for Cefuroxime Dosing during Cardiac Surgery under Cardiopulmonary Bypass.

Authors:  J Lanoiselée; P J Zufferey; S Hodin; N Tamisier; L Gergelé; J C Palao; S Campisi; S Molliex; J Morel; X Delavenne; E Ollier
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  Targeting cefuroxime plasma concentrations during coronary artery bypass graft surgery with cardiopulmonary bypass.

Authors:  Marieke Aalbers; Peter G J ter Horst; Wobbe Hospes; Michel L Hijmering; Alexander J Spanjersberg
Journal:  Int J Clin Pharm       Date:  2015-03-20

10.  Cefuroxime plasma and tissue concentrations in patients undergoing elective cardiac surgery: Continuous vs bolus application. A pilot study.

Authors:  Keso Skhirtladze-Dworschak; Doris Hutschala; Georg Reining; Peter Dittrich; Anna Bartunek; Martin Dworschak; Edda M Tschernko
Journal:  Br J Clin Pharmacol       Date:  2019-02-13       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.